In this webinar, we will discuss design and development of translational in vitro models with better validity for chronic pain drug discovery. We will discuss how to select between animal and human models for your discovery research and how to bridge between rodent-based and human neuronal assays as well as opportunities and limitations of human models from iPS cells and native human nerve tissue.  We will also provide our view on how to address lack of efficacy as early as possible in the drug discovery path by sharing case studies from our lab and from the literature.

Finally, we will share our vision on how to develop “disease in a dish” microfluidic co-culture models to study the interaction between neuronal cells and target organs such as bone and skin in chronic pain. Applying optical electrophysiology in combination with a novel microfluidics platform, we aim to create unique high capacity in vitro assays as means to aid in the understanding of mechanisms of peripheral pain.

Registration for this event is now closed. Contact us to learn more.


Improve translational validity

Learn about Cellectricon’s approach for choosing between rodent and human in vitro models to achieve translatability

Microfluidic co-culture models

Learn about the development and validation of Cellectricon’s new microfluidic assay platform for functional modelling of chronic pain

Presented by:

Paul Karila, PhD, CSO & Director of chronic pain research, Cellectricon AB

Paul joined the company in 2012 as head of Cellectricon’s Discovery Services. He previously worked at AstraZeneca (AZ) where he held leadership positions at the Department of Molecular Pharmacology and later at the department of Neuroscience. At the R&D facilities, Paul led teams responsible for ion channel and GPCR profiling in LI-LO phase, mainly on analgesia targets, and most recently a target identification/target validation team focusing on native (human) tissue. Prior to joining AZ, Paul was a Postdoctoral Fellow at School of Medicine, University of Pittsburgh, USA, studying neurobiology using electrophysiological methods, and a Graduate student in animal physiology at University of Gothenburg, Sweden.

Lydia Moll, Scientist, Cellectricon AB

Lydia started her PhD project at Cellectricon in August 2019 as a part of the EU Marie Skłodowska-Curie ITN-ETN Bone Pain II network. She received her bachelor’s degree in Molecular and Technical Medicine from Furtwangen University (Germany) and graduated with an MSc in Cell and Tissue Engineering at Keele University (UK). Her research projects focused on musculoskeletal diseases and stem cell differentiation. For example, she worked on the establishment of an intervertebral disc organ culture model as well as the evaluation of hydrogel environments on the cartilaginous differentiation of pluripotent stem cells. After graduating Lydia worked as a research fellow on beige Adipose-Organ-on-a-Chip systems at the µ-organo (OoaC) lab at Fraunhofer Institute for Interfacial Engineering and Biotechnology, Stuttgart (Germany).

The webinar is recommended for:

From Pharmaceutical industry and Research Institutes:

Chief Scientific Officers/ Directors/ Heads/ VPs/ Managers/ Senior Scientists/ Principal Scientists/  Neuroscientists/ Project Leaders/ Research Fellows/ Lab Managers/ External Research Solutions managers/ Scientific Collaboration and Business Development managers in:

  • Neuroscience / CNS / chronic pain drug discovery
  • Translational Neuroscience
  • Preclinical research
  • Neuropharmacology/Neurobiology